文献速递前列腺癌

17基因基因组前列腺评分在早期前列腺癌主动监测系列检测中的稳定性

Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
PubMed 文献 · J Urol · 2019-09-06

本研究利用机构泌尿结局数据库,纳入111例初诊Gleason 3+3并选择主动监测、且获得2次17基因GPS结果的男性,评估GPS变化及其与Gleason分级再分类和转为根治性治疗的关系。中位随访64个月期间发生49例(44%)分级再分类,两次活检间GPS平均变化2.1±10.3;首次活检GPS与第二次活检升级相关,首次和第二次GPS均与接受主动治疗相关。

要点

  • 111例主动监测男性中,中位随访64个月发生49例(44%)Gleason分级再分类。
  • 两次活检间GPS平均变化为2.1±10.3,提示GPS随时间变化较小。
  • 首次活检GPS与第二次活检Gleason升级相关,第二次GPS则无显著关联。

核心结论

  • GPS随时间发生小幅度变化;首次和第二次活检的GPS绝对值均与Gleason升级及从主动监测转为主动治疗相关。

研究设计与样本

  • 利用机构泌尿结局数据库,纳入111例初诊Gleason 3+3、选择主动监测并获得2次17基因GPS结果的男性。

主要发现

  • 中位随访64个月,49例(44%)发生Gleason分级再分类(Gleason 3+4或更高)。
  • 首次与第二次活检间GPS平均变化为2.1±10.3。
  • 首次活检GPS(每5单位HR 1.04,95%CI 1.00-1.07,p=0.03)与第二次活检升级相关,第二次GPS(HR 1.02,95%CI 0.99-1.05,p=0.13)与第二次活检升级无显著关联。
  • 首次活检GPS(HR 1.09,95%CI 1.04-1.14,p<0.01)和第二次活检GPS(HR 1.09,95%CI 1.04-1.14,p<0.01)均与接受主动治疗相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Genomic testing may improve risk stratification in men with prostate cancer managed by active surveillance. We aimed to characterize the stability and usefulness of serial genomic test scores in men undergoing serial biopsies during active surveillance. MATERIALS AND METHODS: We compiled clinical and disease characteristics of men on active surveillance using an institutional Urologic Outcomes Database. We included patients initially diagnosed with Gleason 3 + 3 prostate cancer who elected active surveillance and received 2, 17-gene GPS (Genomic Prostate Score) results. We examined the association of GPS results and Gleason grade reclassification (Gleason 3 + 4 or greater) with definitive treatment using multivariable Cox proportional hazards regression models. RESULTS: We identified 111 men who underwent serial genomic testing. There were 49 grade reclassification events (44%) at a median followup of 64 months. The mean ± SD GPS change between the first and second biopsies was 2.1 ± 10.3. The GPS at first biopsy (per 5 units HR 1.04, 95% CI 1.00-1.07, p=0.03) was associated with an upgrade at second biopsy, although the second GPS was not (HR 1.02, 95% CI 0.99-1.05, p=0.13). The first and second GPSs (HR 1.09, 95% CI 1.04-1.14 and HR 1.09, 95% CI 1.04-1.14, each p <0.01) were associated with active treatment. CONCLUSIONS: The GPS undergoes small changes with time. Absolute GPS results at the first and second biopsies were associated with Gleason upgrading and transition from active surveillance to active treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Cedars BE, Washington SL, Cowan JE, et al. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2019. PMID: 30958742. doi:10.1097/JU.0000000000000271

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。